UK drug major GlaxoSmithKline (LSE: GSK) has created an Immunology Network, aiming to link GSK’s work to that of academic scientists focusing on immunology research.
The company is already working with a board of academics who are experts in immunology, and is launching the Immunology Catalyst as a new phase of this initiative. Researchers from GSK will learn new skills from external immunology experts, and these academics will be able to continue their own research while having access to GSK’s technology and learning about pharma research and development. Over the next year, six experts are expected to set up research labs at the GSK facility in Stevenage, UK. After the formal sabbatical has come to an end, collaboration will continue between GSK and the academics.